Skip to Content
Merck
  • Activity and tolerability of domifen bromide in patients affected by acute infectious dental diseases: a double-blind placebo-controlled trial.

Activity and tolerability of domifen bromide in patients affected by acute infectious dental diseases: a double-blind placebo-controlled trial.

International journal of clinical pharmacology research (1983-01-01)
F Scaglione, M Coduri, R Nebuloni, F Fraschini
ABSTRACT

Thirty-one patients (21 M and 10 F), affected by acute infectious dental disease, were treated with domifen bromide (A) or placebo (Pl). It was found that A had a beneficial effect on the results of clinical controls and reduced the need for the concomitant use of an antibiotic (p = 0.001 and p = .008 respectively). Furthermore, after two days of treatment with A, there was a significant decrease in pain and inflammation (p less than 0.01). A alone or in combination with an antibiotic elicits a good response, improves the prognosis and reduces the number of days of illness.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Domiphen bromide, 97%